GPhA Announces 2014 Board of Directors

Published Online: Wednesday, February 19, 2014
Follow Pharmacy_Times:
PRESSS RELEASE

(ORLANDO, FL and WASHINGTON, DC, February 19, 2014) — The Generic Pharmaceutical Association (GPhA) today announced the election of its 2014 Executive Committee and Board of Directors.

Craig Wheeler, President and CEO, Momenta Pharmaceuticals, was elected as GPhA Board Chairman. Wheeler succeeds Tony Mauro, President, Mylan North America.

“I’m honored to be elected as chairman of GPhA’s Board of Directors,” said Wheeler. “Our member companies provide timely access to safe and affordable generic medicines for patients around the globe, putting treatment within reach for hundreds of millions of people. There are so many opportunities ahead for this dynamic industry, and I look forward to contributing to our shared success.”

Generic medicines have saved the U.S. system $1.2 trillion over the past decade and $217 billion in 2012 alone, according to the 2013 Generic Drug Savings in the U.S. report, conducted by IMS Institute for Healthcare Informatics on behalf of GPhA.

“It is a time of extraordinary promise for our industry,” said Ralph G. Neas, President and CEO of GPhA. “Patient safety remains our top priority as the Association leads efforts to preserve and promote access to generic medicines. Chairman Wheeler’s strong leadership will be pivotal as the industry works with the FDA, Congress and stakeholders at all levels of the health care system to improve labeling guidance, establish a framework for interchangeable biologic substitution, meet GDUFA goals, and advocate for policies that encourage generic utilization at home and abroad.”

The 2014-2015 GPhA Board of Directors will be:
  • Carole Ben-Maimon (Impax Laboratories)
  • Doug Boothe (Perrigo Company)
  • Chuck Caprariello (Ranbaxy, Inc.)
  • John Ducker (Fresenius Kabi)
  • Jeff Glazer (Heritage Pharmaceuticals)
  • Peter Goldschmidt (Sandoz US)
  • Tony Mauro (Mylan Inc.)
  • Thomas Moore (Hospira Inc.)
  • Allan Oberman (Teva Americas)
  • Chirag Patel (Amneal Pharmaceuticals)
  • Joseph Renner (Zydus Pharmaceuticals, Inc.)
  • Jeff Watson (Apotex Corporation)
  • Craig Wheeler (Momenta Pharmaceuticals)
  • Paul McGarty (Lupin Pharmaceuticals) (at-large director)
Related Articles
Today, an expert panel at the 2015 Generic Pharmaceutical Association Annual Meeting, “FDA and Industry Perspectives on Quality Culture,” convened to discuss a shared commitment with industry to the highest standards of manufacturing quality and regulatory processes.
The Generic Pharmaceutical Association today announced the election of its 2015 Executive Committee and Board of Directors.
The Generic Pharmaceutical Association and its members applaud the significant progress made by the agency during Commissioner of Food and Drugs Dr. Margaret Hamburg’s six years leading the U.S. Food and Drug Administration. Throughout her tenure, Dr. Hamburg has been a tireless advocate for patient safety and a leader in efforts to assure that FDA decisions are guided by scientific principles.
“The Generic Pharmaceutical Association (GPhA) is deeply disappointed in today’s 21st Century Cures discussion draft. While we appreciate that it is a draft, in its current form, the bill would upset the important balance between creating competition and encouraging innovation in the pharmaceutical marketplace, putting savings at risk and limiting access to affordable medicines for millions of American patients.
Latest Issues
  • photo
    Pharmacy Times
    photo
    Health-System Edition
    photo
    Directions in Pharmacy
    photo
    OTC Guide
    photo
    Generic Supplements
  • photo
    Pharmacy Careers
    photo
    Specialty Pharmacy Times
    photo
    Generic
$auto_registration$